Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients (CROSBI ID 279872)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Dvojković, Anja ; Nikolac Perković, Matea ; Šagud, Marina ; Nedić Erjavec, Gordana ; Mihaljević Peleš, Alma ; Švob Štrac, Dubravka ; Vuksan Ćusa, Bjanka ; Tudor, Lucija ; Kušević, Zorana ; Konjevod, Marcela ; Živković, Maja ; Jevtović, Saša ; Pivac, Nela
engleski
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
Escitalopram and vortioxetine are efficacious antidepressants. They directly target serotonin (5-HT) system, but vortioxetine mechanism of action is distinct from the one of selective serotonin reuptake inhibitors (SSRIs). Treatment with SSRIs decrease platelet 5-HT concentration and increase peripheral brain- derived neurotrophic factor (BDNF) levels. Since vortioxetine has a multimodal mechanism of action, it is expected to have a greater effect on circulatory BDNF concentration, compared to conventional antidepressants. This longitudinal study aimed to explore and compare the effects of 4-weeks of treatment with vortioxetine and escitalopram on plasma BDNF and platelet 5-HT concentration in patients with major depressive disorder (MDD). The results revealed that vortioxetine significantly increased plasma BDNF concentration (p=0.018) and significantly decreased platelet 5-HT concentration (p<0.001). Treatment with escitalopram significantly decreased platelet 5-HT concentration (p <0.001), but it did not affect plasma BDNF concentration (p=0.379). Response to vortioxetine was not predicted by baseline plasma BDNF or platelet 5-HT concentration, but response to escitalopram was predicted by baseline platelet 5-HT concentration. These effects might be due to vortioxetine unique mechanism of action, but the clinical implications are unclear. It remains to be determined whether this finding extends during long-term vortioxetine treatment, and which, if any, clinical effects emerge from BDNF increase.
depression ; escitalopram ; plasma BDNF ; platelet serotonin ; patients ; vortioxetine
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
105
2021.
110016
30
objavljeno
0278-5846
1878-4216
10.1016/j.pnpbp.2020.110016
Povezanost rada
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)